ADAM metallopeptidase with thrombospondin type 1 motif 10Genealiases: ADAM-TS10 · ADAMTS-10 · WMS · WMS1
Q-omics provides the consensus-scored ADAMTS10 profile across patient tissues and cancer cell-line models. ADAMTS10 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ADAMTS10 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ADAMTS10 RNA expression shows 18,981 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where ADAMTS10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAMTS10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAMTS10 survival associations across molecular data types. ADAMTS10 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAMTS10 RNA expression–survival associations across cancer types. High ADAMTS10 expression shows unfavorable associations in OV, LUSC, CESC and KIRC, but favorable associations in HNSC and DLBC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ADAMTS10 RNA expression.
This table summarizes ADAMTS10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ADAMTS10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAMTS10 shows lower tumor expression in UCEC, LUSC and KICH and higher tumor expression in KIRC, LIHC and HNSC. The KIRC box plot shows higher ADAMTS10 RNA expression in tumor versus normal tissue (log2 FC = +1.515, t-test p < 0.001).
This table shows molecular features associated with ADAMTS10 in patient tissues and cancer cell lines. In patient samples, ADAMTS10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAMTS10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
